| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human RALGAPB recombinant protein (Position: M1-H1025) was used as the immunogen for the RALGAPB antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
RALGAPB Antibody / Ral GTPase-activating protein subunit beta is a anti-RALGAPB Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), Immunohistochemistry (IHC), ELISA with listed reactivity in Human, Mouse, Rat.
Key elements and design rationale
- Target: RALGAPB
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, IHC, ELISA
Biological background
RALGAPB is encoded by the RALGAPB gene located on human chromosome 20q13.33. The protein is cytoplasmic and interacts with Ral GTPases to stimulate their intrinsic GTP hydrolysis activity, thereby switching them from active (GTP-bound) to inactive (GDP-bound) states. Through this action, RALGAPB contributes to regulation of endocytosis, exocytosis, and actin cytoskeleton dynamics. It also links Ral signaling to insulin-stimulated GLUT4 vesicle trafficking in metabolic tissues.
The RALGAPB antibody is widely used to detect the 185-200 kDa protein in western blot and to visualize cytoplasmic localization in immunofluorescence. RALGAPB forms a heterodimer with RALGAPA1 or RALGAPA2, and the resulting complex controls Ral-dependent regulation of mTOR signaling, autophagy, and vesicle movement. Studies have implicated RALGAPB in insulin sensitivity, as well as in cancer progression where Ral signaling is hyperactivated. Loss or mutation of RALGAPB leads to sustained Ral activity, promoting cellular proliferation and migration.
Functional studies using this antibody have connected RALGAPB to the modulation of cell junction dynamics and receptor trafficking. It is also implicated in neuronal vesicle regulation and autophagosome maturation.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- Immunohistochemistry: map target signal in tissue context and compare regions/phenotypes.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
